The goal of this clinical trial investigation is to evaluate the tolerance of the T10070 on healthy volunteers by clinical examination under ophthalmological control.

Participants will attend 2 visits (inclusion at day 0 and follow-up/final at D7/D9. After inclusion, subjects will have to apply T10070 6 times a day during 7 to 9 days. The following tasks will be asked to participants:

• ophtalmological examination
• diary completion to record T10070 applications, potential discomfort/reactions observed and medication taken.
• complete subject questionnaire about usability of the product

Inclusion Criteria:

• Informed consent signed and dated
• Subject ≥ 18 years old
• Healthy volunteer
• Normal ocular examination in both eyes
• Normal skin examination in both eyes

Main Exclusion Criteria:

• Far best-corrected visual acuity (BCVA) ≥ +0.1 LogMar (e.g., ≤ 0.8 in decimal value or ≤ 80/100 Snellen equivalent)
• Known or suspected hypersensitivity to one of the components of the T10070
• History of trauma, infection, clinically significant inflammation within the 3 previous months
• Ongoing or know history of ocular allergy and/or uveitis and/or viral infection
• Diagnosed keratoconus
• Any palpebral abnormality